6 reports of this reaction
3.3% of all AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10% reports
#6 most reported adverse reaction
ERYTHEMA is the #6 most commonly reported adverse reaction for AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10%, manufactured by Beiersdorf Inc. There are 6 FDA adverse event reports linking AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10% to ERYTHEMA. This represents approximately 3.3% of all 183 adverse event reports for this drug.
Patients taking AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10% who experience erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERYTHEMA is moderately reported among AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10% users, representing a notable but not dominant share of adverse events.
In addition to erythema, the following adverse reactions have been reported for AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10%:
The following drugs have also been linked to erythema in FDA adverse event reports:
ERYTHEMA has been reported as an adverse event in 6 FDA reports for AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10%. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERYTHEMA accounts for approximately 3.3% of all adverse event reports for AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10%, making it a notable side effect.
If you experience erythema while taking AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.